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Biosurgicals and Trauma
John A. Aucar, Viren Punja and Juan A. Asensio
Abstract
Hemorrhage plays a prominent role in the outcome of trauma patients, from 
initial injury, through resuscitation, and stabilization. Biosurgicals have recently 
drawn attention to both the control of bleeding and chronic wound management. 
However, their role will be examined here in the context of adjuncts to control 
preoperative, intraoperative, and postoperative bleeding in trauma. A review of 
the scientific literature relevant to the use of passive and active topical hemostatic 
devices, as well as systemic pharmacologic agents, for control of hemorrhage is 
provided, in both military and civilian contexts. Bibliometric publication patterns 
and published guidelines are examined to identify the range of individual products 
available and the degree of attention they receive in the management of acute trau-
matic injuries. It is imperative that the evidentiary basis for the use of these agents 
be weighed against their cost and potential risks.
Keywords: biologic glues, fibrin patches, thrombin gels, topical agents, bleeding, 
coagulopathy, hemostasis
1. Introduction
Injuries occur in remote and sometimes austere environments compared to the 
controlled environment of elective surgical procedures. The time from injury to 
definitive control of hemorrhage can vary dramatically according to circumstances. 
Although differences in prehospital transport times has little effect on mortality 
in hemodynamically stable patients, both military and civilian analyses indicate 
prehospital transport times are associated with an increased risk of mortality in 
patients with signs of active bleeding [1, 2].
The natural response to injury leads to the activated coagulation process through 
the intrinsic pathway and extrinsic pathway, which converge on the final common 
pathway, converting prothrombin to thrombin and subsequently fibrinogen to 
fibrin. Excessive bleeding can overcome coagulation reserve through exhaustive 
consumption of coagulation factors and activation of molecular inflammatory pro-
cesses. Resuscitative efforts may result in hemodilution, combined with physiology 
that is dramatically altered due to hypothermia and acidosis. This can be associated 
with overactive fibrinolysis, which heightens the need for local hemorrhage control.
The state of coagulation function must often be assessed clinically. Traditional 
coagulation tests like the PT and PTT are not available in the immediate post injury 
phase and can have limited correlation with bleeding. Contemporary coagulation 
monitoring focuses on the use of functional point-of-care whole blood coagulation 
test such as the activated clotting time (ACT) [3] or thromboelastography (TEG) 
[4] to detect traumatic coagulopathy. The need to control traumatic bleeding at the 
earliest feasible moment, for both the coagulation competent and coagulopathic 
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patient has driven recent interest in the development of adjuncts to hemostasis 
for the management of military and civilian injuries. Mechanical and biosurgical 
adjuncts for hemorrhage control have been designed and tested in prehospital, 
emergency facility, and intraoperative contexts. In addition to applicability for 
extremity injuries, some of these adjuncts are designed with the advantage of 
feasible application to torso and junctional injuries, which are less accessible for 
mechanical control of bleeding.
This chapter will deal mainly with commercially available gauze, absorbable 
matrix, liquid, and foam products, with and without procoagulant activators used 
for the control of bleeding in the context of managing acute trauma.
2. Background on biosurgicals for trauma
2.1 Literature considerations
The term “biosurgical” does not have a reserved place in the National Library 
of Medicine (NLM) medical subject heading (MeSH) tree. Most of the rel-
evant literature can be identified using the disjunctive combination of terms: 
“Hemorrhage/*therapy” OR “fibrin glue” OR “tissue adhesives,” subsequently con-
joined by AND to “wounds and injuries.” A recent Medline search with that strategy 
yielded 748 articles between 1952 and 2019 (searched 10/1/2019). Figure 1 shows the 
5 year period publication pattern of this strategy from 1960 to present. Excluding 
three articles before 1960, it can be seen that modern era of biologic-based adjuncts 
to hemostasis began in the late 1960s, when fractionated blood products began to be 
generally available. However, consideration of the Final Common Pathway factors, 
thrombin (Factor II) and fibrin (Factor I), as adjuncts for surgical bleeding goes 
back as far as World War II [5].
Thrombin was likely the first biologic agent used to stop bleeding. Barber’s and 
boxers were reported to use it to stop bleeding from shaving cuts and fight wounds as 
early as 1892 [6]. Human thrombin has partially replaced the use of bovine throm-
bin to avoid bovine antibodies that disrupt various components of the coagulation 
system, leading to hemorrhagic and thrombotic complications [6]. However, both 
bovine thrombin and human thrombin remain in current usage. Salmon Thrombin-
Fibrin in a lyophilized form is an inexpensive, readily available alternative which 
has supportive data in an animal model [7]. The problem of potential disease 
Figure 1. 
Number of Medline publications each 5 year period 1960 to 2019. Medline search results for: 
“Hemorrhage/*therapy” OR “fibrin glue” OR “tissue adhesives,” AND “wounds and injuries.”
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transmission from human thrombin was resolved with the subsequent development 
of recombinant thrombin. Although thrombin can be used alone, it is commonly 
applied with a carrier such as Gelfoam, made from processed and purified porcine 
skin. Thrombin combined with fibrinogen is the component of fibrin glue, which is 
packaged under various brand names, further elaborated below.
Sources used for this chapter include articles identified by the above search, 
their bibliographic references, and focused Medline searches for specific products. 
The literature dealing with biologic surgical products for hemorrhage control 
can be generally divided into three areas: (1) biochemical property assessment 
(2) comparison of efficacy in standardized animal injury models, and (3) series 
descriptions of clinical use. Animal experiments can be further categorized as using 
models for arterial, venous, or mixed hemorrhage. These usually involve creation of 
standardized injuries. However, different investigators use various injury mecha-
nisms, making direct comparison of results difficult. Among animal trials, there are 
comparisons of single agents to controls and comparisons of multiple agents with or 
without controls.
There are numerous considerations in comparing the results between various 
animal model experiments for control of bleeding. These include differences in the 
rate of bleeding at the time of dressing application; attempts at simulating a realistic 
field-use scenario versus an isolated dressing challenge; consideration of the vessel 
type lacerated and the type and size of laceration; consideration of the duration of 
hemorrhage before application and arterial pressure level at the time of dressing 
application; differences in resuscitation regimens after dressing application, and; 
consideration of whether dressing application is performed with or without prior 
vascular control [8]. Additional problems with many of the animal studies concerns 
the large variance in blood loss volumes within groups, such that the standard 
deviation is often several times the mean blood loss [9]. This makes the detection of 
statistical superiority for any particular hemorrhage control strategy problematic.
Most of the clinical literature related to biosurgical adjuncts for hemorrhage 
control in trauma exists in small series, where a topical agent was applied in prehos-
pital or emergency facility settings. The outcome measures are usually described 
as the subjective assessment of bleeding control and qualitative evaluation of user 
satisfaction with the products. In most clinical series, there is no opportunity to 
measure blood loss or specify time between application and control of bleeding.
2.2 Adjunctive methods for hemorrhage control
There are a number of standard and adjunctive methods for hemorrhage control. 
These include (1) direct, local wound pressure with standard gauze, (2) proximal 
tourniquets to limit extremity bleeding, (3) gauze pads impregnated with procoag-
ulant activators, (4) powdered procoagulant activator agents, (5) absorbable matrix 
agents with or without an added procoagulant, and (6) liquid or foam products with 
reconstituted coagulation factors.
Currently there are a large number of products utilized as adjuncts for hemor-
rhage control. These are grouped by mechanism of action in Tables 1–3, described 
further below. Direct, local wound pressure with gauze, supplemented by the use 
of tourniquets remains the baseline standards to which topical hemostatic agents 
have been compared. A common pitfall of gauze dressings, particularly in the 
hands of the inexperienced, lies in the wide distribution of pressure beneath a 
bulky dressing, when focal pressure at the specific bleeding site is more effective. 
This may lead to inefficient control of hemorrhage and unnecessary blood loss. 
This can also prompt the more aggressive use of limb tourniquets, which promote 
ischemia of a larger downstream soft tissue mass, when local pressure may have 
Biosurgicals - The Next Frontier in Operative Approaches
4
been effective. Tourniquets are limited to use in mid and distal extremity wounds. 
There use is controversial due to a high rate of ineffective application and concerns 
for complications. Improper tourniquet placement, such that constriction is applied 
above venous pressure, but not tight enough to occlude arterial inflow, can promote 
venous bleeding. When properly applied, extended ischemic insult may contribute 
to subsequent compartment syndromes or systemic metabolic stress when the tour-
niquet is removed, and resuscitative efforts ensue. In a 2011 report, Kragh, et al., 
reviewed tourniquet use in 499 soldiers with application of 862 tourniquets to 651 
limbs. Complications of tourniquet use noted in that review, in order of decreasing 
frequency, included amputation, fasciotomy, clotting complications, myonecrosis, 
palsy at the tourniquet site, acute renal failure, significant pain, and rigor [10]. 
However, this was in observational cohort study, without the ability to compare 
potential outcomes with any alternate approach. Tourniquet use was supported 
based on the perception of minor morbidity and infrequent major complications. In 
cases where arterial extremity hemorrhage is difficult to control with point pres-
sure, tourniquet use can be lifesaving.
Much of the early interest and experience with biological adjuncts for hemor-
rhage control comes from the military starting with World War II. The immediate 
Type of agent Main products Components/mechanism of 
action
Uses
Zeolite based QuikClot
Combat 
Gauze(CG)
Combat 
GauzeXL(CGX)
Woundstat
Kaolin -impregnated rolled 
gauze
Activates the intrinsic 
coagulation pathway
Traumatic wound 
treatment for 
high-volume blood 
loss and hemostasis 
in large wounds
Woundstat Smectite + polyacrylic polymer Traumatic wound 
treatment for 
high-volume blood 
loss and hemostasis 
in large wounds
Chitosan-based:
(Chitosan-
polysaccharide 
derived from 
crustacean 
exoskeleton)
Chito Gauze 
(HCG)
Chitoflex (HCF)
(single sided),
Hem Con (HC)
(double sided)
Omni Stat (OS)
Rapidly 
Deployable
Hemostat 
(RDH) & 
Modified Rapidly 
Deployable 
Hemostat 
(mRDH)
Celox-A, 
Celox(CE) 
Granules, Celox 
Gauge(CEG) 
&Celox Rapid 
(CR)
Chitosan/large surface area, 
hemostatic pressure & 
hemostatic agent
Chitosan/cross links RBC’s to 
form a mucoadhesive barrier and 
activates platelets
Traumatic wound 
treatment for 
high-volume blood 
loss and hemostasis 
in large wounds
Table 1. 
Biologically active inorganic stimulants of coagulation for topical application.
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attention available from combat medics, combined with the staged treatment and 
evacuation model of care created incentives to identify portable products and 
reducing the risk of exsanguination between injury and definitive care. Seven 
Criteria for the optimal field dressing has been described by the US military [8]:
Type of agent Main products Components/mechanism of 
action
Uses
Albumin-based Bioglue Bovine serum albumin + 
Glutaraldehyde
Tissue adhesive-seals 
leaks around sutures/
staples in large blood 
vessels
Polyethylene-
glycol-based 
(PEG-based)
Coseal
Duraseal
2 PEG polymers
PEG ester + trilysine amine + 
blue dye
Mechanically sealing 
leaks in peripheral 
vascular reconstructions
Dural sealing
Fibrin-based Tisseel
Quixil, Evicel
Vivostat
Cryoseal
Tachocomb H, 
Tachosil
Vitagel
Tachocomb
Salmon 
Thrombin-
Fibrin
Dry Fibrin 
Sealant 
Dressing 
(DFSD)
Human fibrinogen + Human 
thrombin
Autologous
Human fibrinogen + Human 
thrombin
Bovine collagen + Bovine 
thrombin + Autologous plasma
Human fibrinogen +
Bovine thrombin
Lyophilized salmon + human 
thrombin and human 
fibrinogen
Human fibrinogen + Human 
thrombin + calcium chloride
Adjunct to surgical 
hemostasis, seals tissue 
and stops diffuse 
bleeding
Forms a collagen/fibrin 
platelet scaffold
Mechanical barrier 
to bleeding and also 
provides fibrinogen
Mechanical barrier/
fibrin clot to stop 
bleeding by packing
Table 3. 
Fibrin-based hemostatic tissue sealants.
Type of 
agent
Main 
products
Components/mechanism of 
action
Uses
Gelatin-
based
Gelfoam
Surgifoam
Floseal
Surgiflo
Porcine gelatin
Bovine gelatin + Human 
thrombin
Porcine gelatin +/− Bovine 
thrombin
Mechanical barrier to bleeding-
provides matrix for clot 
formation.
Adjunct to hemostasis on wet, 
actively bleeding tissue
Collagen-
based
Avitene, 
Ultrafoam
Instat, Instat 
MCH
Helistat, 
Helitene
D-Stat
Bovine collagen
Bovine collagen + Bovine 
thrombin
Mechanical barrier to bleeding, 
provide matrix for clot formation
Compression pad or flowable 
solution
Cellulose-
based
Surgicel,
Surgicel 
Nu-knit
Surgicel Snow
Oxycel
Oxidized regenerated cellulose
Oxidized non-regenerated 
cellulose
Mechanical barrier to bleeding, 
denatures blood proteins
Table 2. 
Scaffold-based absorbable matrix adjuncts for surface bleeding.
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1. It should have the ability to stop large vessel bleeding within 2 minutes, even If 
applied to active bleeding or pooled blood;
2. It should be ready for use without premixing or special preparation;
3. It should be simple to apply with minimal training;
4. It should be lightweight and durable;
5. It should be stable and functional at room temperature, plus functional at tem-
perature extremes (between −10° Centigrade and 55° Centigrade);
6. It should safe to use, without risk of tissue damage or disease transmission, and;
7. It should be inexpensive
The introduction of gauze pads impregnated with procoagulant activators has 
raised hopes that a more efficient means of local hemorrhage control, particularly 
in the prehospital setting, could be achieved. There are a variety of such products, 
with various activators, described further below. Table 1 contains a listing of the 
most commonly available products with biologically active inorganic stimulants 
of coagulation for topical application, showing common trade names. Hemostatic 
agents also come in granular form. These provide the opportunity to fill deep 
wound tracks, where direct local pressure is less efficient, and tourniquets are not 
practical. One of the most powerful, kaolin (Zeolite) granules, serves to activate 
the intrinsic pathway through factor XII and rapidly absorbs water in an exother-
mic reaction. It has not found common clinical usage, given its strong associated 
exothermic, hydrophilic reaction, which can cause local tissue damage [11].
As an alternative to gauze, there are a variety of absorbable matrix agents, which 
can be used as temporary topical dressings or left within body cavities for absorp-
tion. These are available with and without the addition of coagulation activators. 
Table 2 shows commonly available products based on a scaffold mechanism.
One of the most common used biosurgical approaches for intraoperative hemor-
rhage control is the direct application of thrombin mixed with fibrinogen in the form 
of a liquid, spray, or foam. This is intended to create a sealant barrier that promotes 
coagulation on bleeding surfaces. There a various products based on a similar bar-
rier layer/sealant approach and are also known as tissue adhesives. These are usually 
applied by mixing a primary component with an activator through a dual chamber 
syringe at the moment of application. These products are represented in Table 3.
2.3 Topical wound dressings for hemorrhage control
Fibrinogen and thrombin were the first two components of the coagulation 
cascade that were isolated, thus they are referred to Factor I and Factor II, respec-
tively. There was extensive early testing of topically applied dried human fibrin 
and thrombin in controlled animal models of liver, spleen and brain injuries. 
Additionally, it was used in a series of human neurosurgical cases, which identi-
fied advantages, included better hemostasis than alternative methods, shortening 
of operative time, ability to leave the absorbable products behind with minimal 
tissue reaction, and producing no impairment of the effects of local antibiotics [12]. 
Subsequent case reports of clinical applications suggested topical biologic procoagu-
lants were well tolerated but led to a consensus that they had only transient effects in 
the control of bleeding. These findings were mostly documented in administrative 
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meeting minutes of the Subcommittee on Blood Substitutes, of the Army’s Division 
of Medical Sciences [5]. Thus, fibrin and thrombin held limited particularly in the 
ensuing years. The combination of thrombin with Gelfoam served as the mainstay 
for bothersome, but limited, intraoperative bleeding from raw surfaces.
Subsequently, there was a resurgence of interest in biologically assisted topical 
hemostatics at the end of the 20th Century, again driven by military relevance. A 
modern version of the dry fibrin sealant dressing (DFSD) was compared to a stan-
dard dry gauze dressing. When applied with direct pressure for 2 minutes DFSD was 
shown to significantly reduce both total blood loss (124 ml ±64 vs. 377 ± 64, P = 0.01) 
and blood loss per kilogram of body weight (1.3 ml/kg ±0.6 vs. 3.8 ml/kg ±0.6, 
P = 0.02) in a ballistically injured goat model. The animal’s mean arterial pressure 
was also preserved with the reduced blood loss [13]. Similar hemorrhage reduction 
was noted when dry fibrin sealant dressing was used in a swine model for packing 
controlled liver injuries in normothermic conditions [14] and hypothermic, hemo-
diluted conditions [15] aimed at simulating the clinical coagulopathy of trauma. The 
product, which has not yet received FDA approval, has been utilized in Afghanistan 
and Iraq under an Investigational New Drug (IND) protocol, with strong military 
proponents. However, clinical data to confirm its effectiveness is elusive.
The Rapid Deployment Hemostat (RDH) ™ (Marine Polymer Technologies, 
Danvers, MA) and modified Rapid Deployment Hemostat (mRDH) have been a key 
component of frontline military hemorrhage control efforts. This dressing is made 
with Poly-N-acetyl glucosamine (pGlcNAc) which is a substance isolated from 
cultures of a marine micro Algae and is FDA approved to treat bleeding in trauma 
patients. The mechanism of action is to induce hemostasis by vasoconstriction, 
erythrocyte agglutination, and RBC and platelet activation. RDH was compared 
to standard linen dressings in a swine model with a standardized 4 mm aortic 
punch wound. Outcome measures were blood loss and survival after removal of 
the dressing and at 2 hours following removal. RDH treated animals had an aver-
age blood loss of 234 ml, compared to 1071 ml in the control animals (p < 0.001). 
These animals also had an 80% survival on release of compression and 2 hours later, 
compared to 40% survival on compression release and 0% survival 2 hours later for 
the controls [16].
Another topical dressing which consists of gauze combined with a coagula-
tion activator is marketed as QuikClot Combat Gauze ®. The activator, Kaolin, is 
hydrated aluminum silicate, also known as Porcelain or China clay. It belongs to a 
broader category of Zeolite substances and forms a microgranular white powder 
which is biologically inert except as a binder. However, when ingested orally it is 
known to activate coagulation Factor XII thereby stimulating the intrinsic clotting 
cascade. It is commonly used as an activator for the Activated Clotting Time (ACT) 
and in Thromboelastography (TEG). QuikClot was introduced in 2002 as a gauze 
bandage substitute for actively bleeding wounds. However, it entered mainstream 
military use in 2008. In 2013 it gained FDA approval and has gained increasing 
support for civilian management of surgical bleeding and traumatic wounds. It 
is commonly available in various configurations of pads and rolls for prehospital, 
emergency room, and operating room application. It carries a low risk of allogenic 
reactions due to a lack of shellfish, human, or animal proteins. Both military and 
civilian case series report successful prehospital control of bleeding in 70–90% of 
applications of QuikClot [17, 18], however, most of the reported support is based on 
survey data [18], due to the difficulty of obtaining objective clinical data.
QuikClot was evaluated against standard gauze for the control of hemorrhage in 
a 2012 porcine groin injury model. Blood loss and stability of hemorrhage control 
when stressed by limb motion were the primary outcomes. It was found to signifi-
cantly reduce blood loss and produce a stable clot which resisted recurrent bleeding 
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with movement in the injured groin. Bleeding in the experimental group ranged 
from 0 to 514 ml (mean = 50, SD ± 154 ml) and the control group ranged from 0 
to 1002 ml (mean = 351, SD ± 354 ml). The number of movements tolerated before 
rebleeding in the experimental group ranged from 3 to 40 (mean = 36.6 ± 11) and 
for control group ranged from 0 to 9 (mean = 0.9 ± 2.7). Both outcomes showed 
statistically significant difference by Multivariate Analysis of Variance, although 
specific tests designed for high Variance and non-normal data distributions were 
not described [19].
There are several case series reporting the use of QuikClot to stop bleeding in 
the field and emergency rooms. In a multi-institutional clinical series reported 
in 2008, QuikClot combat gauze was applied in 103 cases, including 83 cases 
involving external use and 20 cases of intracorporeal use by civilian and military 
personnel. The overall success rate for control of bleeding was 92%. The reported 
failures were attributed to coagulopathy or inability to apply the product directly 
to the source of hemorrhage [20]. This study used self-reported survey data to 
assess effectiveness, illustrating again the difficulty in obtaining objective clini-
cal data.
Zeolite impregnated gauze in the form of Combat Gauze ™ and Trauma Pads ™ 
have also been used for temporary intra-abdominal packing during damage control 
laparotomy. Choron, in a 2017 retrospective review, compared 28 patients packed 
with QuikClot plus laparotomy pads to 40 patients that underwent standard lapa-
rotomy pad packing as part of damage control maneuvers. There were no distin-
guishing clinical characteristics between the two groups, except that the patient’s 
packed with QuikClot gauze plus laparotomy packs received approximately twice 
the number of packed red cells and fresh frozen plasma (10 vs. 5 and 8 vs. 4, 
respectively) at the time of initial operation. This suggests they may have had more 
serious and hemorrhage prone injuries. Blood products transfused after the initial 
operation were similar. There were no significant differences noted in multiple out-
come variables, including: number of subsequent operations, days until abdominal 
closure, total fluid requirements, infectious complications, bowel complications, 
and length of stay. Hospital mortality was 29% in those who received QuikClot 
packing and 28% in those who did not. While the study did not show superiority 
of Zeolite product, it was interpreted to indicate safety in the context of damage 
control and supported further clinical studies in that setting [21].
Zeolite has been studied in the form of granules directly applied to bleeding 
wounds and within a containment bag, which simultaneously absorbs water from 
blood, activates platelets and the clotting cascade, plus applies local pressure as 
process progresses. However, the hydrophilic process is associated with an exother-
mic reaction severe enough to produce local burns [22]. A modified formulation of 
granules (QuikClot Advanced Clotting Sponge+ ®, Z-Medica Corp., Wallingford, 
CT) has been developed which reduces the exothermic risk by partial prehydration. 
This product reduced bleeding in a porcine femoral artery injury model as effec-
tively as the unhydrated product, with minimal measured temperature elevation 
and without exothermic injury to the tissues [23].
An alternate procoagulant incorporated into topical dressings to promote 
hemostasis is Chitosan. It consists of a linear, positively charged polysaccharide 
derived from chitin, a compound of natural origin obtained from the shell of crabs 
and shellfish. There are numerous chemical variations based on cross-linking the 
Chitosan backbone to inert or biologically active agents, including antimicrobials. It 
has been studied for several biomedical uses including tissue engineering scaffolds, 
drug/gene delivery systems, hemostasis materials, antibacterial materials, and 
wound dressing. It promotes hemostasis by various mechanisms, not all of which 
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are fully understood [23]. It is reported to form a mucoadhesive barrier in wounds 
by cross-linking red blood cells.
There are numerous Chitosan based products (see Table 1) with availability 
varying by market. Chitosan based products have been compared to each other 
and to Zeolite based products in various animal experiments. In a 2018 con-
trolled rat model, Stricker-Krongrad, et al. showed that Opticell ™ (Medline 
Industries, Chicago, Ill) dressing could effectively reduce blood loss from 
excisional dermal wounds, even in the presence of heparin [24]. De Castro et al. 
compared a modi-fied preparation of Chitosan, created by adding a polymerized 
hydrophobic side chain to the naturally hydrophilic Chitosan backbone, to stan-
dard Chitosan, and to standard dressing in a swine model. Hemodynamic stabil-
ity after splenectomy was required to avoid autotransfusion from the animal’s 
contractile spleen. A 4.4 mm diameter arteriotomy using a vascular punch was 
then performed to create a standardized injury in the exposed femoral artery. 
After 30 seconds of free bleeding, one of the two test dressings or the standard 
dressing was applied, and post treatment blood loss was measured. Eight animals 
subjected to standard gauze as the means for hemostasis all exsanguinated. Six 
of eight animals managed with a typical Chitosan dressing achieved hemostasis. 
Eight of eight animals treated with the Chitosan dressing modified by adding 
a hydrophobic component achieved hemostasis with survival to the endpoint. 
Hemorrhage control with both of the Chitosan based dressings was statistically 
superior to standard gauze. The Chitosan variants were not statistically differ-
ent compared to each other, but the authors support the use of the hydrophilic 
modification as superior [25].
A similarly structured study using 36 swine randomized to three groups com-
pared the efficacy of standard gauze to Celox Rapid ™ (Medtrade, Crewe, UK) 
gauze and QuikClot Combat Gauze ™ (Z-Medica, Wallingford, CT). This study 
use a 6 mm lateral femoral arteriotomy and allowed 60 seconds of free hemorrhage 
prior to wound packing with one of the three study materials. Each animal received 
a 500 cc bolus resuscitation consisting of a solution hetastarch solution at the time 
of wound packing. The animals in each group had similar pretreatment charac-
teristics. All 12 animals in each group survived to the study endpoint. Dressing 
failure, defined as blood spilling beyond the confines of the wound and dressing 
was assessed at 120 minutes and recurrent bleeding was assessed as a secondary 
outcome. There were two dressing failures in the standard gauze group and two in 
the Zeolite based QuikClot group, but none in the Chitosan based Celox group. This 
did not reach statistical significance [26].
Clinical Experience with HemCon ™, a topical gauze dressing impregnated 
with freeze-dried Chitosan was described in 2006. Effective hemostasis was 
achieved with HemCon in 97% of 68 wounded soldiers, with wounds involv-
ing the head and neck, torso, and extremities [27]. A 2017 study utilizing the 
Department of Defense Trauma Registry identified 28,222 soldiers injured in 
the Iraq and Afghanistan conflict with and Abbreviated Injury Score (AIS) of 
three or greater. Specialized hemostatic gauze products were used in only 259 
(0.9%) of cases. Although the brand of product was not always identified in 
the registry, the type of product was identified. Of the 259 patients, 58 patients 
received chitosan-based dressings (HemCon ™ Gauze, or Celox ™ Gauze) and 
201 patients received kaolin-based dressings (QuikClot ™ Combat Gauze). In an 
extensive comparison of the cohorts, those who were managed with a hemostatic 
adjunct were noted have higher Injury Severity Scores (ISS) and received greater 
amounts of blood component therapy but had no statically significant difference 
in mortality [28].
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3. Biosurgical agents for operative hemorrhage control
3.1 General considerations for operative hemorrhage control
Control of cavitary hemorrhage can be one of the most challenging aspects of 
trauma surgery. Mechanical control of large vessel bleeding by suture ligation, 
mechanical clips, arteriography or venography, primary anastomosis, or interposi-
tion grafts are the mainstays of hemostasis. In addition to vascular bleeding, rapid, 
reliable control of solid organ bleeding is one of the top imperatives in trauma 
care. The highly vascularized hepatic parenchyma and those of spleen and kidneys 
are subject to persistent bleeding when injured. In this setting, clotting factor 
consumption combined with dilution by crystalloid resuscitation or massive blood 
component transfusion induce patients to develop coagulopathy. Damage control 
techniques involve the immediate control of life-threatening hemorrhage, followed 
by an extended period of resuscitation and stabilization, with the aim of restor-
ing normal physiology, prior to staged definitive repair of injuries [29]. It is in the 
interest of the trauma surgeon to control organ surface bleeding as soon and as 
effectively as possible at the initial operative episode.
Adjunctive agents for the control of bleeding have found role in both damage 
control and definitive repair contexts. In damage control procedures, recurrent 
bleeding stimulated by removal of packing agents is an additional risk. Surgeons are 
faced with the consideration of using non-adhesive materials, which only provide 
mechanical compression, but do not debride clots on removal, versus adherent, 
procoagulant materials, which must either be absorbable or risk clot debridement 
upon removal. Potential roles for these agents include reduction of vascular suture 
line bleeding, control of parenchymal bleeding from liver injury, splenic salvage, or 
reduction of splenic bed bleeding after splenectomy.
3.2 Specific product adjuncts for intraoperative hemorrhage control
Biosurgical products that have found a role for intraoperative control of bleeding 
include collagen-based, gelatin-based, cellulose-based, albumin-based, polyeth-
ylene glycol-based (PEG)-based, and polysaccharide-based hemostatic adjuncts 
to standard mechanical techniques. These commonly work through distinct, 
but similar mechanisms that produce mechanical barriers to bleeding. Collagen 
and cellulose based products form a scaffold matrix promoting adherence of red 
cells, platelets, and clotting factors onto the bleeding surface. They are generally 
absorbable and can be left in the operative wound with limited risk. The remaining 
products are dual component fluids that when mixed, form biocompatible chemi-
cally bonded hydrogels, which create an adherent layer bound to tissues, and may 
achieve hemostasis when suturing, ligation, or cautery have failed. These agents are 
associated with extensive clinical publications, although most available data is in the 
form of case reports or case series. These establish feasibility and safety, but there is 
little comparative data in a controlled clinical setting.
The Surgicel ™ (Johnson & Johnson, New Brunswick, NJ) line of products is 
made of oxidized regenerated cellulose available in the form of loosely knitted 
sheets, microfibrillar sheets, or powder. Oxycel ™, (BD, Franklin Lakes, NJ) is a 
similar oxidized, non- regenerated cellulose product. These can be applied to bleed-
ing surfaces but are less effective in coaguloapthic models [30]. Oxycel, sutured into 
a polyglycolic acid mesh has been described to promote splenic salvage after injury 
[31]. This product has also been placed laparoscopically to control bleeding from 
a penetrating wound of the liver [32]. Oxidized cellulose products are commonly 
placed intraoperatively and left in place, since they slowly absorb. The products are 
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bacteriostatic, but not bactericidal. Bacteriologic seeding is uncommon, but abscess 
formation has been reported. Additionally, the material can trap gas bubbles and 
have a radiologic appearance very similar to abscess on postoperative CT scans. In a 
blinded evaluation of 18 cases, radiologists misinterpreted the appearance of these 
products as abscess or other pathology 90% of the time [33]. Performance improved 
to 80% accuracy when they were informed of the presence of Surgicel prior to CT 
scan interpretation. A rare but dramatic complication, spinal cord compression, has 
been reported with the use of Surgicel in proximity to the spine after elective and 
trauma related procedures [34, 35].
Agents considered mechanical hemostats including cellulose, collagen, polysac-
charides, and gelatins are generally only effective for minor surface bleeding and 
in patients with an intact coagulation system. Agents which produce an adhesive 
barrier and those which are based on fibrin plus thrombin are considered preferred 
when there is a derangement of the coagulation system. There are several com-
mercially available products based on fibrin plus thrombin generally known as 
fibrin glue (see Table 3). These are usually applied as a liquid with a double barrel 
syringe. As soon as the two components are mixed, they begin to form a substitute 
for natural clot. Low pressure gas-powered spray applicators are also available for 
covering broader surfaces. Injection of these materials into the wound tracks, either 
by hand or spray, is considered dangerous, due to the potential for air or thrombus 
embolization. There is extensive cased based literature describing the use of fibrin 
glue in the context of trauma and in elective surgery, across several subspecialties. 
However, there is no high-level evidence that it reduces blood component usage or 
improves outcomes.
4. Conclusion
The role of biosurgical products in trauma care is not yet fully defined. There is 
a widely held belief that modified field dressings that incorporate procoagulants, 
whether organic or inorganic, are more efficient for stopping wound bleeding 
in accessible wounds. There is ongoing interest in testing similar agents for torso 
injuries and deep wounds. There is some supportive, but not conclusive evidence 
from animal studies that these agents can control arterial bleeding, including large 
vessel injuries, at least as temporizing maneuvers, until definitive surgical repair 
can be performed. Data from controlled animal models indicate that these agents 
are effective, but the results of comparative trials are mixed.
This is partly due to inherent difficulties in standardizing the injury model and 
a physiologic response to injury. Adhesive barrier products also have an evolving 
role in the control of small vessel and organ surface bleeding, although controlled 
comparative trials are missing. Coagulation system derangements commonly 
encountered in trauma patients adds an additional level of complexity to interpret-
ing the data. The use of modified gauze packing during damage control laparotomy 
remains of great interest, but the use of common cotton laparotomy pads remains 
the standard approach. Numerous subspecialty applications have been described 
for management of urologic, gynecologic, and facial injuries. The supportive data is 
similarly structured.
Clinical support for the use of modified dressings, adhesive barrier agents, and 
fibrin glue remains largely anecdotal and relies heavily on satisfaction and subjec-
tive assessment of effectiveness. It is unlikely that rigorous research protocols are 
feasible in the clinical context of acute trauma. This is partly due to the inherent 
difficulties in trauma research. Patient consent to participate in research protocols 
is impractical to obtain and waived consent protocols are difficult to design and 
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conduct. Meanwhile, sporadic reports continued to emerge of complications 
associated with various specific products that rely on either mechanical properties 
or coagulation system effects to promote hemostasis. The risk to benefit ratio of 
biosurgical products used in a trauma context remains essentially unknown. The 
potential remains for extensive future research on the use of these products as 
adjuncts for trauma care in both civilian in military contexts.
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